Benign Prostatic Hyperplasia (BPH)
Prostate gland enlargement causing urinary obstruction. MSC therapy reduces prostatic inflammation and promotes tissue remodeling to improve urinary flow.
Benign prostatic hyperplasia is the non-cancerous enlargement of the prostate gland that occurs progressively in aging men. It affects over 50% of men by age 60 and 90% by age 85. BPH causes lower urinary tract symptoms (LUTS) including urinary hesitancy, weak stream, incomplete bladder emptying, nocturia, and urinary urgency — significantly impairing quality of life and sleep.
The pathogenesis of BPH involves hormonal factors (DHT-driven epithelial and stromal proliferation) and chronic prostatic inflammation, which amplifies the hyperplastic process. Standard management includes alpha-blockers, 5-alpha-reductase inhibitors, and surgical interventions (TURP, laser therapy) — but medications have limited efficacy, and surgery carries risks of sexual dysfunction and incontinence.
MSC therapy is being explored as a regenerative approach to BPH — targeting the chronic prostatic inflammation driving tissue hyperplasia, with the goal of reducing prostate volume and improving urinary flow without surgical intervention.
MSCs suppress the chronic prostatic inflammation that drives BPH progression — reducing M1 macrophage-driven TNF-α and IL-1β in the prostate tissue, promoting M2 macrophage polarization that supports tissue remodeling, and inhibiting fibroblast-to-myofibroblast transition that stiffens the prostatic stroma. Anti-fibrotic paracrine signals may reduce the smooth muscle hypertonicity contributing to obstructive symptoms.
Early clinical experience with local prostatic MSC injection has documented improvements in International Prostate Symptom Score (IPSS), urinary flow rate (Qmax), and post-void residual volume in treated patients. Prostate volume reduction has been observed on MRI at 6-month follow-up in some patients.
True Regen coordinates PSA, prostate MRI or ultrasound, IPSS scoring, and uroflowmetry before treatment. Regen Cord evaluates each case to determine whether systemic IV infusion, local injection, or a combination protocol is most appropriate.
- Reduced International Prostate Symptom Score (IPSS)
- Improved urinary flow rate (Qmax)
- Decreased post-void residual volume
- Reduction in prostate volume on imaging
- Improved sleep quality from reduced nocturia
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.